Paul Muntner1, Robert M Carey2, Samuel Gidding3, Daniel W Jones4, Sandra J Taler5, Jackson T Wright6, Paul K Whelton7. 1. Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: pmuntner@uab.edu. 2. Department of Medicine, University of Virginia, Charlottesville, Virginia. 3. Nemours Cardiac Center, A. I. DuPont Hospital for Children, Wilmington, Delaware. 4. Department of Medicine, University of Mississippi, Jackson, Mississippi. 5. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota. 6. Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, Cleveland, Ohio. 7. Department of Epidemiology, Tulane University, New Orleans, Louisiana.
Abstract
BACKGROUND: The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults provides recommendations for the definition of hypertension, systolic and diastolic blood pressure (BP) thresholds for initiation of antihypertensive medication, and BP target goals. OBJECTIVES: This study sought to determine the prevalence of hypertension, implications of recommendations for antihypertensive medication, and prevalence of BP above the treatment goal among U.S. adults using criteria from the 2017 ACC/AHA guideline and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). METHODS: The authors analyzed data from the 2011 to 2014 National Health and Nutrition Examination Survey (N = 9,623). BP was measured 3 times following a standardized protocol and averaged. Results were weighted to produce U.S. population estimates. RESULTS: According to the 2017 ACC/AHA and JNC7 guidelines, the crude prevalence of hypertension among U.S. adults was 45.6% (95% confidence interval [CI]: 43.6% to 47.6%) and 31.9% (95% CI: 30.1% to 33.7%), respectively, and antihypertensive medication was recommended for 36.2% (95% CI: 34.2% to 38.2%) and 34.3% (95% CI: 32.5% to 36.2%) of U.S. adults, respectively. Nonpharmacological intervention is advised for the 9.4% of U.S. adults with hypertension who are not recommended for antihypertensive medication according to the 2017 ACC/AHA guideline. Among U.S. adults taking antihypertensive medication, 53.4% (95% CI: 49.9% to 56.8%) and 39.0% (95% CI: 36.4% to 41.6%) had BP above the treatment goal according to the 2017 ACC/AHA and JNC7 guidelines, respectively. CONCLUSIONS: Compared with the JNC7 guideline, the 2017 ACC/AHA guideline results in a substantial increase in the prevalence of hypertension, a small increase in the percentage of U.S. adults recommended for antihypertensive medication, and more intensive BP lowering for many adults taking antihypertensive medication.
BACKGROUND: The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults provides recommendations for the definition of hypertension, systolic and diastolic blood pressure (BP) thresholds for initiation of antihypertensive medication, and BP target goals. OBJECTIVES: This study sought to determine the prevalence of hypertension, implications of recommendations for antihypertensive medication, and prevalence of BP above the treatment goal among U.S. adults using criteria from the 2017 ACC/AHA guideline and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). METHODS: The authors analyzed data from the 2011 to 2014 National Health and Nutrition Examination Survey (N = 9,623). BP was measured 3 times following a standardized protocol and averaged. Results were weighted to produce U.S. population estimates. RESULTS: According to the 2017 ACC/AHA and JNC7 guidelines, the crude prevalence of hypertension among U.S. adults was 45.6% (95% confidence interval [CI]: 43.6% to 47.6%) and 31.9% (95% CI: 30.1% to 33.7%), respectively, and antihypertensive medication was recommended for 36.2% (95% CI: 34.2% to 38.2%) and 34.3% (95% CI: 32.5% to 36.2%) of U.S. adults, respectively. Nonpharmacological intervention is advised for the 9.4% of U.S. adults with hypertension who are not recommended for antihypertensive medication according to the 2017 ACC/AHA guideline. Among U.S. adults taking antihypertensive medication, 53.4% (95% CI: 49.9% to 56.8%) and 39.0% (95% CI: 36.4% to 41.6%) had BP above the treatment goal according to the 2017 ACC/AHA and JNC7 guidelines, respectively. CONCLUSIONS: Compared with the JNC7 guideline, the 2017 ACC/AHA guideline results in a substantial increase in the prevalence of hypertension, a small increase in the percentage of U.S. adults recommended for antihypertensive medication, and more intensive BP lowering for many adults taking antihypertensive medication.
Authors: Sripal Bangalore; Bora Toklu; Eugenia Gianos; Arthur Schwartzbard; Howard Weintraub; Gbenga Ogedegbe; Franz H Messerli Journal: Am J Med Date: 2017-01-19 Impact factor: 4.965
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: Nancy R Cook; Jeffrey A Cutler; Eva Obarzanek; Julie E Buring; Kathryn M Rexrode; Shiriki K Kumanyika; Lawrence J Appel; Paul K Whelton Journal: BMJ Date: 2007-04-20
Authors: Stephan Lüders; Joachim Schrader; Jürgen Berger; Thomas Unger; Walter Zidek; Michael Böhm; Martin Middeke; Wolfgang Motz; Cornelia Lübcke; Andrea Gansz; Ludmer Brokamp; Roland E Schmieder; Peter Trenkwalder; Herrmann Haller; Peter Dominiak Journal: J Hypertens Date: 2008-07 Impact factor: 4.844
Authors: Eleni Rapsomaniki; Adam Timmis; Julie George; Mar Pujades-Rodriguez; Anoop D Shah; Spiros Denaxas; Ian R White; Mark J Caulfield; John E Deanfield; Liam Smeeth; Bryan Williams; Aroon Hingorani; Harry Hemingway Journal: Lancet Date: 2014-05-31 Impact factor: 79.321
Authors: Sandra Costa Fuchs; Carlos E Poli-de-Figueiredo; José A Figueiredo Neto; Luiz César N Scala; Paul K Whelton; Francisca Mosele; Renato Bandeira de Mello; José F Vilela-Martin; Leila B Moreira; Hilton Chaves; Marco Mota Gomes; Marcos R de Sousa; Ricardo Pereira E Silva; Iran Castro; Evandro José Cesarino; Paulo Cesar Jardim; João Guilherme Alves; André Avelino Steffens; Andréa Araujo Brandão; Fernanda M Consolim-Colombo; Paulo Ricardo de Alencastro; Abrahão Afiune Neto; Antônio C Nóbrega; Roberto Silva Franco; Dario C Sobral Filho; Alexandro Bordignon; Fernando Nobre; Rosane Schlatter; Miguel Gus; Felipe C Fuchs; Otávio Berwanger; Flávio D Fuchs Journal: J Am Heart Assoc Date: 2016-12-13 Impact factor: 5.501
Authors: Yuichiro Yano; Jared P Reis; Laura A Colangelo; Daichi Shimbo; Anthony J Viera; Norrina B Allen; Samuel S Gidding; Adam P Bress; Philip Greenland; Paul Muntner; Donald M Lloyd-Jones Journal: JAMA Date: 2018-11-06 Impact factor: 56.272
Authors: Fawaz Al Ammary; Xun Luo; Abimereki D Muzaale; Allan B Massie; Deidra C Crews; Madeleine M Waldram; Mohamud A Qadi; Jacqueline Garonzik-Wang; Macey L Henderson; Daniel C Brennan; Alexander C Wiseman; Richard C Lindrooth; Jon J Snyder; Josef Coresh; Dorry L Segev Journal: Clin J Am Soc Nephrol Date: 2019-06-25 Impact factor: 8.237
Authors: Paul Muntner; Paula T Einhorn; William C Cushman; Paul K Whelton; Natalie A Bello; Paul E Drawz; Beverly B Green; Daniel W Jones; Stephen P Juraschek; Karen L Margolis; Edgar R Miller; Ann Marie Navar; Yechiam Ostchega; Michael K Rakotz; Bernard Rosner; Joseph E Schwartz; Daichi Shimbo; George S Stergiou; Raymond R Townsend; Jeff D Williamson; Jackson T Wright; Lawrence J Appel Journal: J Am Coll Cardiol Date: 2019-01-29 Impact factor: 24.094
Authors: Linnea A Polgreen; Barry L Carter; Philip M Polgreen; Peter M Snyder; Daniel K Sewell; Emine O Bayman; Shelby L Francis; Jacob E Simmering; Christopher Parker; Rachel Finkelstein Journal: Contemp Clin Trials Date: 2020-10-07 Impact factor: 2.226
Authors: Jordan Kho; Xiaoyu Tian; Wing-Tak Wong; Terry Bertin; Ming-Ming Jiang; Shan Chen; Zixue Jin; Oleg A Shchelochkov; Lindsay C Burrage; Anilkumar K Reddy; Hong Jiang; Reem Abo-Zahrah; Shuangtao Ma; Ping Zhang; Karl-Dimiter Bissig; Jean J Kim; Sridevi Devaraj; George G Rodney; Ayelet Erez; Nathan S Bryan; Sandesh C S Nagamani; Brendan H Lee Journal: Am J Hum Genet Date: 2018-08-02 Impact factor: 11.025
Authors: Karen L Margolis; Steven P Dehmer; JoAnn Sperl-Hillen; Patrick J O'Connor; Stephen E Asche; Anna R Bergdall; Beverly B Green; Rachel A Nyboer; Pamala A Pawloski; Nicole K Trower; Michael V Maciosek Journal: Hypertension Date: 2020-08-31 Impact factor: 10.190